MIROCALS Clinical Study: Qualilab’s Role
The following article, published on May 24, 2025, in The Lancet, acknowledges Qualilab’s participation in the MIROCALS study, an honor for which we are very proud:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00262-4/fulltext
Amyotrophic lateral sclerosis (ALS) is a life-threatening disease characterized by progressive motor neuron loss and limited therapeutic options. The MIROCALS study tested the hypothesis that low-dose interleukin-2 (IL-2LD) improves survival and function in ALS.
From the study’s initiation through to the final communication of results, the Qualilab team acted as an independent body, providing quality support and audit activities, thereby contributing to the integrity, traceability, and reliability of the study data.
Need clinical quality guidance?
